These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3038639)

  • 1. Clinical studies with treated clotting factor concentrates.
    Colombo M; Mannucci PM
    Dev Biol Stand; 1987; 67():333-6. PubMed ID: 3038639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virus safety of pasteurized factor VIII and factor IX concentrates: study in virgin patients.
    Heimburger N; Karges HE; Weidmann E
    Dev Biol Stand; 1987; 67():303-10. PubMed ID: 3038638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The incidence of HTLV-III/LAV seroconversion and non-A, non-B hepatitis in recipients of plasma products.
    Piszkiewicz D; Kingdon H; Lee ML; Hooper J
    Dev Biol Stand; 1987; 67():327-31. PubMed ID: 2440745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of antibodies to LAV/HTLV III in hemophiliacs with the use of virus-inactivated clotting factors.
    Dietz B; Klose HJ; Gürtler L; Eberle J; Deinhardt F; Köhler-Vajta K; Peller P
    Thromb Haemost; 1986 Aug; 56(1):50-2. PubMed ID: 3095947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [HTLV-III antibodies and immunologic changes in hemophilic children. Prevalence of HTLV-III antibodies in hemophilic children and their relatives living in the same household].
    Zenz W; Muntean W; Teubl I; Beaufort F; Heinz FX
    Padiatr Padol; 1987; 22(1):33-41. PubMed ID: 3108827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of heat-treated clotting-factor concentrates in patients with haemophilia and a high exposure to HTLV-III.
    McGrath KM; Thomas KB; Herrington RW; Turner PJ; Taylor L; Ekert H; Schiff P; Gust ID
    Med J Aust; 1985 Jul; 143(1):11-3. PubMed ID: 2989666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and biological survey of haemophilia A and B patients infused with French heat-treated concentrates.
    Parquet A; Boneu B; Bosser C; Cazenave JP; Dirat G; Gazengel G; Grunebaum L; Sultan Y; Verroust F; Wiesel ML
    Nouv Rev Fr Hematol (1978); 1988; 30(4):205-7. PubMed ID: 3143099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dry-heating of coagulation factor concentrates at 80 degrees C for 72 hours on transmission of non-A, non-B hepatitis. Study Group of the UK Haemophilia Centre Directors on Surveillance of Virus Transmission by Concentrates.
    Lancet; 1988 Oct; 2(8615):814-6. PubMed ID: 2902265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revision of the protocol recommended for studies of safety from hepatitis of clotting factor concentrates. International Society for Thrombosis and Hemostasis.
    Mannucci PM; Colombo M
    Thromb Haemost; 1989 Jun; 61(3):532-4. PubMed ID: 2508261
    [No Abstract]   [Full Text] [Related]  

  • 10. Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.
    White GC; DiMichele D; Mertens K; Negrier C; Peake IR; Prowse C; Schwaab R; Yoshioka A; Ingerslev J
    Thromb Haemost; 1999 Mar; 81(3):462. PubMed ID: 10102478
    [No Abstract]   [Full Text] [Related]  

  • 11. [Therapy-induced hepatitis risk in hemophilia patients].
    Schiller WG; Renger FG
    Z Arztl Fortbild (Jena); 1983; 77(19):807-10. PubMed ID: 6417919
    [No Abstract]   [Full Text] [Related]  

  • 12. Virus safety of beta-propiolactone treated plasma preparations. Clinical experiences.
    Heinrich D; Sugg U; Brackmann HH; Stephan W; Lissner R
    Dev Biol Stand; 1987; 67():311-7. PubMed ID: 3649316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Viral hepatitis in hemophiliac patients treated with commercial concentrates of factors VIII and IX].
    Miranda ML; Lissen E; Vinuesa M; Jiménez JM; García de Pesquera F; Leal M
    Med Clin (Barc); 1985 Apr; 84(13):516-9. PubMed ID: 3923278
    [No Abstract]   [Full Text] [Related]  

  • 14. [No HCV seroconversion in hemophilia following substitution with virus-inactivated coagulation factor VIII and IX concentrates].
    Perret BA; Morell A; Bütler-Brunner E; Burckhardt JJ
    Schweiz Med Wochenschr; 1991 Nov; 121(44):1621-3. PubMed ID: 1658928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current safety of clotting factor concentrates.
    Epstein JS; Fricke WA
    Arch Pathol Lab Med; 1990 Mar; 114(3):335-40. PubMed ID: 2407224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates.
    Goldsmith JC
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):203-15. PubMed ID: 10759015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serological evidence that dry heating of clotting factor concentrates prevents transmission of non-A, non-B hepatitis.
    Skidmore SJ; Pasi KJ; Mawson SJ; Williams MD; Hill FG
    J Med Virol; 1990 Jan; 30(1):50-2. PubMed ID: 2106006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
    Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
    Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Transmission of the human immunodeficiency virus by a dry heat-treated Factor VIII concentrate?].
    Weisser J
    Klin Padiatr; 1988; 200(5):375-9. PubMed ID: 3141670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative protein chemistry studies on Factor VIII concentrates].
    Kienast K; Trobisch H
    Arzneimittelforschung; 1984; 34(8):895-900. PubMed ID: 6437415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.